In practice, as thresholds for AFP and HCG levels can be employed pragmatically for detecting the malignant NGGCT components YST and CHC, respectively,5 the main clinical priority is for a second noninvasive microRNA panel that could distinguish the typically AFP/HCG “marker-negative” malignant GCT subtypes germinoma/seminoma versus EC. This evidence concerns the gene AFP and granular cell tumor.